A Phase 3 interventional study of GWP42003-P and Placebo in Rett Syndrome and RTT, sponsored by Jazz Pharmaceuticals. Terminated at 26 sites in 4 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-09-02.
Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Rett Syndrome with a site in United States — 11 open to participants now, 21 under way, 5 of them phase 3. Rett Syndrome · United States.
Among the 55 studies in Rett Syndrome with a site in United States, this one is the 20th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2019, is one of 11 in phase 3, and was the 27th registered.
96 studies on the registry are indexed under Rett Syndrome; 19 are open to participants now.
Browse Rett Syndrome studies →11 of the 55 studies in Rett Syndrome with a site in United States are open now. Recruiting first, the newest first:
Biomed Industries, Inc. · Sites in United States, Australia
Ages 5–20 · Women only
UCB BIOSCIENCES, Inc. · Sites in United States, Belgium, France and 9 more countries
Ages 5–35
University of Rochester · Sites in United States
Ages 2+ · Healthy volunteers
University of Minnesota · Sites in United States
Ages 18–99
Ionis Pharmaceuticals, Inc. · Sites in United States, Austria, Canada and 2 more countries
Ages 2–65 · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Rett Syndrome studies recruiting now, 4 (29%) set no upper age limit and 7 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.
This study: 2 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 14
First in 2004; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is close to the median of 30 across 64 interventional studies indexed under Rett Syndrome.
Median enrollment 32 across the 34 interventional studies, 146 across the 21 observational. Of the 31 that completed or were terminated, 14 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 55 have an industry lead sponsor. The 10 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Jazz Pharmaceuticals has 2 studies filed under Rett Syndrome — fewer than ten, so there is no comparison to draw.
10 of the studies in Rett Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06840496Phase 3Biomed Industries, Inc.To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome | 2027-09-30 |
| NCT06338267Rett Syndrome Research TrustValidating Innovative Biosensors for Rett Autonomic Symptom Tracking | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06139172Rush University Medical CenterWeb Intervention for Parents of Youth With Genetic Syndromes (WINGS) | 2026-12 |
| NCT05012475Georgetown UniversityMeasuring Impact of Computer Gaming on Arm Use in Rett Syndrome | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 55 studies in Rett Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of cannabidiol oral solution (GWP42003-P, CBD-OS) in reducing symptom severity when compared with placebo, in participants with Rett syndrome.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 milligrams per milliliter (mg/mL) GWP42003-P oral solution. Taken twice daily (morning and evening).
Drug: GWP42003-P
100 mg/mL GWP42003-P oral solution. Taken twice daily (morning and evening).
Drug: GWP42003-P
Placebo oral solution (0 mg/mL GWP42003-P) volume matched to 5 mg/kg/day or 15 mg/kg/day GWP42003-P. Taken twice daily (morning and evening).
Drug: Placebo
GWP42003-P presented as an oral solution containing cannabidiol
Also known as: Cannabidiol, CBD, Epidiolex, CBD-OS
Matching placebo oral solution
Change From Baseline in the Mean Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score at Week 24 for the 15 mg/kg/Day GWP42003-P Dose Level Compared With Placebo
RSBQ is a caregiver-completed questionnaire that measures the frequency of current disease characteristics (45 items) in individuals with Rett Syndrome. Each item is rated on a 3-point scale (0-2); 0 indicating an item that is "not true as far as you know," 1 indicating an item is "somewhat or sometimes true," and 2 indicating an item that is "very true or often true." Item 31 ("Uses eye gaze to convey feelings, needs and wishes") is reverse scored (0 indicating "very true or often true", 1 indicating "somewhat or sometimes true," and 2 indicating "not true as far as you know"). The total summed score ranges from 0 to 90, with higher scores representing greater severity.
Time frame: Baseline; Week 24
Change From Baseline in the Mean RSBQ Total Score at Week 24 for the 5 mg/kg/Day GWP42003-P Dose Level Compared With Placebo
RSBQ is a caregiver-completed questionnaire that measures the frequency of current disease characteristics (45 items) in individuals with Rett Syndrome. Each item is rated on a 3-point scale (0-2); 0 indicating an item that is "not true as far as you know," 1 indicating an item is "somewhat or sometimes true," and 2 indicating an item that is "very true or often true." Item 31 ("Uses eye gaze to convey feelings, needs and wishes") is reverse scored (0 indicating "very true or often true", 1 indicating "somewhat or sometimes true," and 2 indicating "not true as far as you know"). The total summed score ranges from 0 to 90, with higher scores represent greater severity.
Time frame: Baseline; Week 24
Mean Clinical Global Impressions - Improvement (CGI-I) Score at Week 24
CGI-I is a 7-point scale that requires the clinician to assess how much a participant's illness has improved or worsened relative to a Baseline state at the beginning of the intervention. This is rated as: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse.
Time frame: Baseline; Week 24
Change From Baseline in Mean Clinician Global Impressions - Severity (CGI-S) Score at Week 24
CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment relative to the clinician's experience with participants who had the same diagnosis. This is rated as: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; or 7 = extremely ill.
Time frame: Baseline; Week 24
Change From Baseline in Mean RSBQ Subscale Scores at Week 24
RSBQ is a caregiver-completed questionnaire that measures the frequency of current disease characteristics in individuals with Rett Syndrome. The 45-item RSBQ is comprised of 8 subscales: 1) general mood (score range 0-16), 2) breathing problems (range 0-10), 3) hand behaviors (range 0-12), 4) face movements (range 0-8), 5) body rocking (BR)/expressionless face (range 0-12), 6) night-time behaviors (range 0-6), 7) anxiety/fear (range 0-8), 8) walking/standing (range 0-4). Each item is rated on a 3-point scale (0-2); 0 indicating an item that is "not true as far as you know," 1 indicating an item is "somewhat or sometimes true," and 2 indicating an item that is "very true or often true." Item 31 ("Uses eye gaze to convey feelings, needs and wishes") is reverse scored (0 indicating "very true or often true", 1 indicating "somewhat or sometimes true," and 2 indicating "not true as far as you know"). Higher scores representing greater severity. CFB = Change from Baseline.
Time frame: Baseline; Week 24
Change From Baseline in Mean 9-items Motor Behavioral Assessment (MBA-9) Total Score and Subscale Scores at Week 24
MBA-9 is derived from the full MBA scale (37 Rett syndrome symptoms) by selecting the items deemed amenable to change and which reflected areas of meaningful clinical change. the MBA-9 includes 9 items (1-Regression of motor skills; 2-Poor eye/social contact; 3-Lack of sustained interest; 4-Does not reach for objects or people; 5-Chewing difficulties; 6-Speech disturbance; 7-Hand clumsiness; 8-Dystonia and 9-Hypertonia/rigidity); for each item, the severity of current symptoms is rated by the investigator on a 5-point numerical scale ranging from 0 to 4 with higher scores representing greater severity (0 = normal or never; 1 = mild or rare; 2 = moderate or occasional; 3 = marked or frequent; 4 = very severe or constant). Total MBA-9 score was calculated by summing the scores of 9 different subscale items. The total summed score ranges from 0 to 36, with higher scores representing greater severity. CFB = Change from Baseline.
Time frame: Baseline; Week 24
Change From Baseline in Mean Children's Sleep Habits Questionnaire (CSHQ) Total Score and Subscale Scores at Week 24
CSHQ is a caregiver-completed sleep screening instrument designed for school-aged children; which includes 33 items within 8 subscales: 1) bedtime resistance (score range 6-18), 2) sleep onset delay (range 1-3), 3) sleep duration (range 3-9), 4) sleep anxiety (range 4-12), 5) night wakings (range 3-9), 6) parasomnias (range 7-21), 7) sleep-disordered breathing (range 3-9), 8) daytime sleepiness (range 8-24). Item scores range from 1 to 3, where 3="usually" (≥5 times/week), 2="sometimes" (2-4 times/week), and 1="rarely" (≤1 time/week); for items 31 and 32; 3=fall asleep, 2=very sleepy, 1=not sleepy. In general, a score of 3 indicates greater severity, however, 6 items (1-Goes to bed at same time; 2-Falls asleep in 20 minutes; 3-Falls asleep in own bed; 10-Sleeps the right amount; 11-Sleeps same amount each day; 26-Wakes by himself) are reverse scored. Total summed score ranges from 33 to 99, with higher scores representing more disturbed sleep behavior. CFB = Change from Baseline.
Time frame: Baseline; Week 24
| Milestone | 5 mg/kg/Day GWP42003-P | 15 mg/kg/Day GWP42003-P | Placebo |
|---|---|---|---|
| Started | 10 | 9 | 10 |
| Completed | 7 | 6 | 4 |
| Not completed | 3 | 3 | 6 |
| Withdrew: Withdrawal of consent due to covid-19 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Withdrawal (covid-19) | 0 | 2 | 0 |
| Withdrew: Physician decision | 2 | 1 | 3 |
| Withdrew: Sponsor decision - covid-19 precaution | 0 | 0 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 |
RSBQ is a caregiver-completed questionnaire that measures the frequency of current disease characteristics (45 items) in individuals with Rett Syndrome. Each item is rated on a 3-point scale (0-2); 0 indicating an item that is "not true as far as you know," 1 indicating an item is "somewhat or sometimes true," and 2 indicating an item that is "very true or often true." Item 31 ("Uses eye gaze to convey feelings, needs and wishes") is reverse scored (0 indicating "very true or often true", 1 indicating "somewhat or sometimes true," and 2 indicating "not true as far as you know"). The total summed score ranges from 0 to 90, with higher scores representing greater severity.
| units on a scale | 15 mg/kg/Day GWP42003-P | Placebo |
|---|---|---|
| Baseline | 45.9 ± 16.77 | 50.0 ± 7.56 |
| Change from Baseline at Week 24 | -12.1 ± 13.63 | -6.1 ± 7.22 |
RSBQ is a caregiver-completed questionnaire that measures the frequency of current disease characteristics (45 items) in individuals with Rett Syndrome. Each item is rated on a 3-point scale (0-2); 0 indicating an item that is "not true as far as you know," 1 indicating an item is "somewhat or sometimes true," and 2 indicating an item that is "very true or often true." Item 31 ("Uses eye gaze to convey feelings, needs and wishes") is reverse scored (0 indicating "very true or often true", 1 indicating "somewhat or sometimes true," and 2 indicating "not true as far as you know"). The total summed score ranges from 0 to 90, with higher scores represent greater severity.
| units on a scale | 5 mg/kg/Day GWP42003-P | Placebo |
|---|---|---|
| Baseline | 39.8 ± 12.80 | 50.0 ± 7.56 |
| Change from Baseline at Week 24 | 0.4 ± 12.51 | -6.1 ± 7.22 |
CGI-I is a 7-point scale that requires the clinician to assess how much a participant's illness has improved or worsened relative to a Baseline state at the beginning of the intervention. This is rated as: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse.
| units on a scale | 5 mg/kg/Day GWP42003-P | 15 mg/kg/Day GWP42003-P | Placebo |
|---|---|---|---|
| Mean Clinical Global Impressions - Improvement (CGI-I) Score at Week 24 | 3.2 ± 1.20 | 2.9 ± 1.07 | 3.1 ± 0.38 |
CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment relative to the clinician's experience with participants who had the same diagnosis. This is rated as: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; or 7 = extremely ill.
| units on a scale | 5 mg/kg/Day GWP42003-P | 15 mg/kg/Day GWP42003-P | Placebo |
|---|---|---|---|
| Baseline | 4.3 ± 1.25 | 4.2 ± 0.67 | 4.4 ± 0.84 |
| Change from Baseline at Week 24 | -0.1 ± 0.33 | -0.1 ± 0.38 | 0.0 ± 0.00 |
RSBQ is a caregiver-completed questionnaire that measures the frequency of current disease characteristics in individuals with Rett Syndrome. The 45-item RSBQ is comprised of 8 subscales: 1) general mood (score range 0-16), 2) breathing problems (range 0-10), 3) hand behaviors (range 0-12), 4) face movements (range 0-8), 5) body rocking (BR)/expressionless face (range 0-12), 6) night-time behaviors (range 0-6), 7) anxiety/fear (range 0-8), 8) walking/standing (range 0-4). Each item is rated on a 3-point scale (0-2); 0 indicating an item that is "not true as far as you know," 1 indicating an item is "somewhat or sometimes true," and 2 indicating an item that is "very true or often true." Item 31 ("Uses eye gaze to convey feelings, needs and wishes") is reverse scored (0 indicating "very true or often true", 1 indicating "somewhat or sometimes true," and 2 indicating "not true as far as you know"). Higher scores representing greater severity. CFB = Change from Baseline.
| units on a scale | 5 mg/kg/Day GWP42003-P | 15 mg/kg/Day GWP42003-P | Placebo |
|---|---|---|---|
| Baseline General Mood Score | 6.0 ± 3.65 | 8.2 ± 4.58 | 8.9 ± 3.14 |
| CFB General Mood Score | -0.6 ± 2.70 | -4.9 ± 2.67 | -2.6 ± 2.57 |
| Baseline Breathing Problems Score | 4.7 ± 2.45 | 5.0 ± 3.08 | 5.0 ± 3.43 |
| CFB Breathing Problems Score | 0.2 ± 1.86 | -1.0 ± 1.53 | -0.3 ± 1.25 |
| Baseline Hand Behaviors Score | 7.8 ± 2.15 | 7.6 ± 3.54 | 9.1 ± 2.08 |
| CFB Hand Behaviors Score | 0.7 ± 2.24 | -0.9 ± 3.29 | 0.1 ± 0.90 |
| Baseline Face Movements Score | 2.3 ± 2.45 | 4.6 ± 2.13 | 4.3 ± 2.21 |
| CFB Face Movements Score | 0.0 ± 1.12 | -1.4 ± 1.72 | -0.1 ± 1.07 |
| Baseline Body Rocking/Expressionless Face Score | 4.5 ± 2.59 | 5.1 ± 1.96 | 5.4 ± 2.59 |
| CFB Body Rocking/Expressionless Face Score | 0.6 ± 2.46 | -0.6 ± 1.13 | -0.1 ± 1.86 |
| Baseline Night-time Behaviors Score | 0.8 ± 1.14 | 0.8 ± 0.97 | 1.8 ± 1.69 |
| CFB Night-time Behaviors Score | 0.2 ± 0.97 | -0.1 ± 1.46 | -0.3 ± 1.11 |
| Baseline Anxiety/Fear Score | 4.0 ± 1.89 | 4.6 ± 2.46 | 5.1 ± 1.45 |
| CFB Anxiety/Fear Score | -0.2 ± 1.92 | -1.3 ± 2.29 | -1.7 ± 0.95 |
| Baseline Walking/Standing Score | 2.7 ± 1.64 | 2.1 ± 1.36 | 2.9 ± 1.29 |
| CFB Walking/Standing Score | 0.9 ± 2.09 | 0.0 ± 0.58 | 0.1 ± 1.07 |
MBA-9 is derived from the full MBA scale (37 Rett syndrome symptoms) by selecting the items deemed amenable to change and which reflected areas of meaningful clinical change. the MBA-9 includes 9 items (1-Regression of motor skills; 2-Poor eye/social contact; 3-Lack of sustained interest; 4-Does not reach for objects or people; 5-Chewing difficulties; 6-Speech disturbance; 7-Hand clumsiness; 8-Dystonia and 9-Hypertonia/rigidity); for each item, the severity of current symptoms is rated by the investigator on a 5-point numerical scale ranging from 0 to 4 with higher scores representing greater severity (0 = normal or never; 1 = mild or rare; 2 = moderate or occasional; 3 = marked or frequent; 4 = very severe or constant). Total MBA-9 score was calculated by summing the scores of 9 different subscale items. The total summed score ranges from 0 to 36, with higher scores representing greater severity. CFB = Change from Baseline.
| units on a scale | 5 mg/kg/Day GWP42003-P | 15 mg/kg/Day GWP42003-P | Placebo |
|---|---|---|---|
| Baseline Regression of Motor Skills | 2.2 ± 1.23 | 2.6 ± 0.88 | 2.6 ± 0.84 |
| CFB Regression of Motor Skills | 0.3 ± 1.58 | -0.3 ± 0.49 | 0.0 ± 0.58 |
| Baseline Poor Eye/Social Contact | 1.7 ± 0.82 | 1.6 ± 1.01 | 1.5 ± 0.97 |
| CFB Poor Eye/Social Contact | 0.0 ± 0.87 | -0.1 ± 0.69 | -0.9 ± 1.07 |
| Baseline Lack of Sustained Interest | 1.8 ± 0.79 | 2.1 ± 1.17 | 1.5 ± 0.71 |
| CFB Lack of Sustained Interest | 0.0 ± 0.71 | -0.3 ± 1.11 | -0.1 ± 0.38 |
| Baseline Does Not Reach for Objects or People | 2.0 ± 1.25 | 1.9 ± 1.05 | 2.3 ± 1.25 |
| CFB Does Not Reach for Objects or People | -0.4 ± 2.24 | -0.4 ± 0.98 | 0.1 ± 1.21 |
| Baseline Chewing Difficulties | 1.3 ± 1.34 | 1.3 ± 0.50 | 1.1 ± 0.74 |
| CFB Chewing Difficulties | -0.2 ± 0.67 | 0.0 ± 0.00 | 0.4 ± 0.53 |
| Baseline Speech Disturbance | 3.0 ± 0.47 | 2.8 ± 0.83 | 2.7 ± 0.48 |
| CFB Speech Disturbance | 0.0 ± 0.00 | 0.0 ± 0.58 | 0.3 ± 0.49 |
| Baseline Hand Clumsiness | 2.8 ± 1.14 | 2.8 ± 1.56 | 3.1 ± 1.10 |
| CFB Hand Clumsiness | -0.6 ± 1.33 | -0.4 ± 1.13 | 0.0 ± 0.58 |
| Baseline Dysonia | 1.0 ± 1.41 | 1.2 ± 1.56 | 1.0 ± 1.41 |
| CFB Dysonia | 0.4 ± 1.42 | -0.1 ± 0.90 | 0.1 ± 1.46 |
| Baseline Hypertonia/Rigidity | 1.4 ± 1.51 | 1.1 ± 1.45 | 1.0 ± 1.41 |
| CFB Hypertonia/Rigidity | 0.4 ± 0.73 | -0.1 ± 0.38 | 0.0 ± 1.00 |
| Baseline MBA-9 Total Score | 17.2 ± 5.81 | 17.3 ± 6.78 | 16.8 ± 5.96 |
| CFB MBA-9 Total Score | 0.0 ± 4.87 | -1.9 ± 4.06 | 0.0 ± 3.92 |
CSHQ is a caregiver-completed sleep screening instrument designed for school-aged children; which includes 33 items within 8 subscales: 1) bedtime resistance (score range 6-18), 2) sleep onset delay (range 1-3), 3) sleep duration (range 3-9), 4) sleep anxiety (range 4-12), 5) night wakings (range 3-9), 6) parasomnias (range 7-21), 7) sleep-disordered breathing (range 3-9), 8) daytime sleepiness (range 8-24). Item scores range from 1 to 3, where 3="usually" (≥5 times/week), 2="sometimes" (2-4 times/week), and 1="rarely" (≤1 time/week); for items 31 and 32; 3=fall asleep, 2=very sleepy, 1=not sleepy. In general, a score of 3 indicates greater severity, however, 6 items (1-Goes to bed at same time; 2-Falls asleep in 20 minutes; 3-Falls asleep in own bed; 10-Sleeps the right amount; 11-Sleeps same amount each day; 26-Wakes by himself) are reverse scored. Total summed score ranges from 33 to 99, with higher scores representing more disturbed sleep behavior. CFB = Change from Baseline.
| units on a scale | 5 mg/kg/Day GWP42003-P | 15 mg/kg/Day GWP42003-P | Placebo |
|---|---|---|---|
| Baseline Total Score | 49.8 ± 9.75 | 46.7 ± 4.90 | 49.4 ± 5.42 |
| CFB Total score | -1.6 ± 6.17 | -5.0 ± 6.14 | -3.7 ± 4.07 |
| Baseline Bedtime resistance | 9.2 ± 3.43 | 7.3 ± 2.12 | 7.0 ± 1.25 |
| CFB Bedtime resistance | 0.0 ± 1.00 | -0.4 ± 1.27 | -0.1 ± 1.68 |
| Baseline Sleep onset delay | 1.5 ± 0.71 | 1.4 ± 0.53 | 1.8 ± 0.79 |
| CFB Sleep onset delay | 0.1 ± 1.27 | -0.1 ± 0.69 | -0.6 ± 0.53 |
| Baseline Sleep duration | 4.7 ± 2.41 | 3.4 ± 0.73 | 4.5 ± 1.58 |
| CFB Sleep duration | 0.4 ± 1.13 | -0.3 ± 0.95 | -0.4 ± 1.72 |
| Baseline Sleep anxiety | 5.6 ± 1.65 | 4.6 ± 0.73 | 4.9 ± 1.10 |
| CFB Sleep anxiety | -0.1 ± 0.78 | -0.1 ± 0.38 | 0.0 ± 1.15 |
| Baseline Night wakings | 5.3 ± 2.36 | 4.4 ± 1.33 | 4.6 ± 1.43 |
| CFB Night wakings | -0.4 ± 0.88 | -0.6 ± 1.40 | 0.1 ± 0.69 |
| Baseline Parasomnias | 11.0 ± 1.49 | 10.4 ± 1.42 | 11.7 ± 2.63 |
| CFB Parasomnias | -0.6 ± 1.51 | -1.1 ± 1.68 | -1.4 ± 2.30 |
| Baseline Sleep disordered breathing | 4.2 ± 1.69 | 4.0 ± 1.22 | 3.7 ± 1.06 |
| CFB Sleep disordered breathing | -0.4 ± 1.74 | -0.9 ± 1.07 | -0.1 ± 0.38 |
| Baseline Daytime sleepiness | 11.6 ± 3.20 | 13.2 ± 2.39 | 13.7 ± 2.50 |
| CFB Daytime sleepiness | -0.7 ± 3.64 | -1.4 ± 2.07 | -1.3 ± 2.56 |
Collected over Up to approximately 207 days. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 5 mg/kg/Day GWP42003-P | 0/11 (0%) | 2/11 (18.2%) | 9/11 (81.8%) |
| 15 mg/kg/Day GWP42003-P | 0/9 (0%) | 2/9 (22.2%) | 7/9 (77.8%) |
| Placebo | 0/9 (0%) | 1/9 (11.1%) | 7/9 (77.8%) |
| Event | 5 mg/kg/Day GWP42003-P | 15 mg/kg/Day GWP42003-P | Placebo |
|---|---|---|---|
| COVID-19Infections and infestations | 1/11 | 1/9 | 1/9 |
| Alanine aminotransferase increasedInvestigations | 0/11 | 1/9 | 0/9 |
| Aspartate aminotransferase increasedInvestigations | 0/11 | 1/9 | 0/9 |
| DyskinesiaNervous system disorders | 0/11 | 1/9 | 0/9 |
| Lower respiratory tract infectionInfections and infestations | 1/11 | 0/9 | 0/9 |
| Event | 5 mg/kg/Day GWP42003-P | 15 mg/kg/Day GWP42003-P | Placebo |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 1/11 | 0/9 | 3/9 |
| LethargyNervous system disorders | 0/11 | 3/9 | 0/9 |
| DiarrhoeaGastrointestinal disorders | 2/11 | 2/9 | 0/9 |
| VomitingGastrointestinal disorders | 0/11 | 2/9 | 0/9 |
| PyrexiaGeneral disorders | 0/11 | 2/9 | 1/9 |
| Decreased appetiteMetabolism and nutrition disorders | 0/11 | 2/9 | 0/9 |
| InsomniaPsychiatric disorders | 1/11 | 0/9 | 2/9 |
| NasopharyngitisInfections and infestations | 2/11 | 0/9 | 1/9 |
| EosinophiliaBlood and lymphatic system disorders | 0/11 | 0/9 | 1/9 |
| MacrocytosisBlood and lymphatic system disorders | 1/11 | 0/9 | 1/9 |
One participant assigned to the 5 mg/kg/Day placebo group was misdosed with 5 mg/kg/Day GWP42003-P. The participant was included in the 5 mg/kg/Day placebo group in the Intent-to-Treat Set but was included in the 5 mg/kg/day GWP42003-P group in the Safety Analysis Set (for which Baseline data are reported).
| Age, Categorical(Participants) | 5 mg/kg/Day GWP42003-P | 15 mg/kg/Day GWP42003-P | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 11 | 9 | 9 | 29 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | 5 mg/kg/Day GWP42003-P | 15 mg/kg/Day GWP42003-P | Placebo | Total |
|---|---|---|---|---|
| Mean | 9.7 ± 6.02 | 10.7 ± 3.64 | 8.6 ± 5.53 | 9.7 ± 5.11 |
| Sex: Female, Male(Participants) | 5 mg/kg/Day GWP42003-P | 15 mg/kg/Day GWP42003-P | Placebo | Total |
|---|---|---|---|---|
| Female | 11 | 9 | 9 | 29 |
| Male | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 5 mg/kg/Day GWP42003-P | 15 mg/kg/Day GWP42003-P | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 10 | 9 | 9 | 28 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2019 to primary completion in Jan 2021, 17 months.
Results were first posted in Dec 2021, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol